Call for Abstract

21st International Conference on Radiooncology & Combinatorial Cancer Therapies, will be organized around the theme Contemporary paradigms in Radiooncology and Combination Therapies

Radiooncology 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Radiooncology 2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Biophysical/molecular/functional imaging strategies.
  • Molecular basis of the efficacy of carbon ion/particle radiotherapy

                                                    

 

  •  Radiopharmaceutical/ Radiotracers.
  •  Radioisotopes
  • Radionuclide therapy

 

 

1. Immuno therapy

  •  Immune checkpoint therapy
  •   Dendritic Cell therapy

2. Adoptive cellular therapy

 

  • Chimeric Antigen Receptor (CAR) T-cell therapy
  •  Endogenous T-cell (ETC) therapy
  • Tumor infiltrating lymphocyte (TIL) therapy

 

 Tailoring to New Treatment

 Fusion Improving Accuracy

Dose Tracking 

Automation of protocols 

·         Computed tomography scanners

·         CT contrast agents

·         CT angiography (CTA and CCTA)

·         CT perfusion

·         Spectral CT (dual-source CT)

                            Iterative reconstruction dose reduction software

 

Image Guided Radiation Therapy (IGRT )

Rapid Arc Technology

Intensity Modulated Radiation Therapy (IMRT)

Prostate Seed Implant Prostate Brachytherapy

Breast Brachytherapy

Respiratory Gating 

Trilogy Radiosurgery

Linear Accelerators ( LINAC)

Focused Ultrasound

Stereotactic Body Radiation therapy(SBRT)

Proton therapy

Four-dimensional adaptive radiotherapy

Pluridirectional High-energy Agile Scanning Electron Radiotherapy (PHASER)

       
    \r\n
  • \r\n Clinical Trials in Lung Cancer
  • \r\n
  • \r\n Clinical Trials in Breast Cancer
  • \r\n
  • \r\n Clinical Trials in Head & Neck Cancer
  • \r\n
  • \r\n Clinical Trials in Brain Cancer
  • \r\n

\r\n

\r\n  

\r\n

    \r\n
  • \r\n Liposomal Mitomycin C and Radiation
  • \r\n
  • \r\n Nanotherapeutics and Chemoradiation
  • \r\n
  • \r\n Nanoparticle Radiosensitizers
  • \r\n
  • \r\n Radiation Directed Drug Delivery
  • \r\n

\r\n

\r\n  

\r\n

    \r\n
  • \r\n Promises and Pitfalls of Genomic Profiling
  • \r\n
  • \r\n Diagnostic Assays for Radiotherapy Effectiveness
  • \r\n
  • \r\n Circulating Tumor DNA (ctDNA)
  • \r\n

\r\n

\r\n  

\r\n

    \r\n
  • \r\n Treatment plan optimization.
  • \r\n
  • \r\n Treatment unit development.
  • \r\n
  • \r\n Radiobiological models for radiotherapy.
  • \r\n
  • \r\n Radiation Dosimetry.
  • \r\n
  • \r\n Nuclear medicine, particularly PET camera diagnostics.
  • \r\n
  • \r\n Magnetic resonance imaging.
  • \r\n

\r\n

\r\n  

\r\n

Immunotherapy or immune targeted gene therapy

CD4+ and CD8+ T lymphocytes response to tumor antigen presented with MHC

Dendritic cell-based immunotherapy

Ribozyme-mediated knock out of the cancer cell

Particle-mediated gene transfer foster immunotherapy

Radiation therapy

SNAG and Clinical Hindrance of Radio Immunogenetic Therapy

Targeted Therapy